Evidence map›Paper›PMID 35401240›Full record

ArticleFrontiers in pharmacology2022

Therapeutic Targeting of Endosome and Mitochondrial Reactive Oxygen Species Protects Mice From Influenza Virus Morbidity.

Eunice E To, Jonathan R Erlich, Felicia Liong, Stella Liong, Raymond Luong, Osezua Oseghale, Mark A Miles, Paris C Papagianis, Kylie M Quinn, Steven Bozinovski and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Antioxidants (Basel, Switzerland) · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Eunice E ToSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Jonathan R ErlichSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Felicia LiongSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Stella LiongSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Raymond LuongDepartment of Pharmacology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.
Osezua OseghaleSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Mark A MilesSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Paris C PapagianisSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Kylie M QuinnSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Steven BozinovskiSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Ross VlahosSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Robert D BrooksCancer Research Institute and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.
John J O'LearySir Patrick Dun's Laboratory, Central Pathology Laboratory, Department of Histopathology Trinity College Dublin, Dublin, Ireland.
Doug A BrooksCancer Research Institute and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.
Stavros SelemidisSchool of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
RMIT University · AUUniversity of South Australia · AUMonash University · AUTrinity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent need to develop effective therapeutic strategies including immunomodulators to combat influenza A virus (IAV) infection. Influenza A viruses increase ROS production, which suppress anti-viral responses and contribute to pathological inflammation and morbidity. Two major cellular sites of ROS production are endosomes

Indexed as

airway inflammationendosomeinflammationinfluenza A viruslung inflammationmitochondriaNADPH oxidasereactive oxygen

Identifiers

PMID35401240
PMCPMC8984148
OpenAlexW4220863329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.